All In MedTech

Device Trial Radar · NCT05230524

DIAMOND AF Post-Approval Study

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

84

Actual

Start

Feb 28, 2022

Primary completion

Dec 17, 2025

Study completion Dec 17, 2025

Sponsor

Lead sponsor
Medtronic Cardiac Ablation SolutionsPublic (MDT)
Sponsor type
Industry
First posted
Feb 9, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial

Conditions

  • Paroxysmal Atrial Fibrillation

Interventions

  • DiamondTemp™ Ablation SystemDevice

    Pulmonary vein isolation will be performed with the DiamondTemp™ Ablation System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)Time frame: 36 month
  2. Freedom from Primary Safety EventsTime frame: 12 months

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Florida Electrophysiology LLC

    Winter Park, Florida

  • Centre Hospitalier de Pau - Hôpital François Mitterrand

    Pau, France

  • Reunion University Hospital - Saint Pierre

    Saint-Pierre, France

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.